Ranbezolid

Ranbezolid
Clinical data
Other namesRBX-7644
Identifiers
  • N-{[(5S)-3-(3-Fluoro-4-{4-[(5-nitro-2-furyl)methyl]-1-piperazinyl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H24FN5O6
Molar mass461.450 g·mol−1
3D model (JSmol)
  • CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCN(Cc4oc(cc4)[N+](=O)[O-])CC3)c(F)c2
  • InChI=1S/C21H24FN5O6/c1-14(28)23-11-17-13-26(21(29)33-17)15-2-4-19(18(22)10-15)25-8-6-24(7-9-25)12-16-3-5-20(32-16)27(30)31/h2-5,10,17H,6-9,11-13H2,1H3,(H,23,28)/t17-/m0/s1

Ranbezolid (RBx7644) is an oxazolidinone antibacterial. It competitively inhibits monoamine oxidase-A (MAO-A).[1]

References

  1. ^ Naruganahalli KS, Shirumalla RK, Bansal V, Gupta JB, Das B, Ray A (September 2006). "Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats". European Journal of Pharmacology. 545 (2–3): 167–72. doi:10.1016/j.ejphar.2006.06.065. PMID 16899241.
Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.